Canntab Therapeutics Ltd

Full interview: Canntab receives indication of patentability for its release cannabidiol formulation

Canntab Therapeutics (CSE:PILL.CN-OTCQX: CTABF) Chief Financial Officer Richard Goldstein joined Steve Darling from Proactive Investors Vancouver on Skype with news that the company has received an initial assessment from the Geneva-based International Preliminary Report on Patentability regarding their Immediate Release Cannabidiol Formulation.

Goldstein talks about what that means for the company going forward and how this fall will be a defining moment for the company. 

Quick facts: Canntab Therapeutics Ltd

Price: $0.60

Market: CSE
Market Cap: $15.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...



Canntab Therapeutics hoping to bring their slow release tablet tech to U.S.

CannTab Therapeutics (CSE:PILL) CEO Jeff Renwick and Chief Financial officer Richard Goldstein sat down with Steve Darling from Proactive Investors at the LD Microcap conference in Los Angeles to talk about their company and their slow release tablets. They also chatted about the U.S. market...

on 4/6/19

2 min read